不同剂量头孢噻肟钠用于肺癌根治术围术期预防术后感染疗效比较
|
摘要
目的探讨肺癌根治术围术期使用不同剂量头孢噻肟钠预防术后感染的疗效和安全性。方法选取2015年2月至2016年8月医院收治的行肺癌根治术患者92例,随机分为大剂量组和小剂量组,各46例,围术期分别予3 g和1.5 g头孢噻肟钠预防术后感染。结果两组患者术后感染发生率均为6.52%(P>0.05);小剂量组用药不良反应发生率为2.17%,明显低于大剂量组的13.04%(P<0.05);两组患者治疗后白蛋白、血红蛋白、白细胞水平均明显优于治疗前(P<0.05),但组间比较无明显差异(P>0.05)。结论肺癌根治术围术期使用小剂量头孢噻肟钠可有效预防术后感染,改善机体营养,且安全性高,值得临床推广。
Objective To investigate the efficacy and safety of different doses of cefotaxime in the prevention of postoperative infection in perioperative period of radical resection of lung cancer. Methods Totally 92 patients with radical resection of lung cancer from February 2015 to August 2016 were randomly divided into the high dose group and the low dose group,46 cases in each group. The high dose group was treated with 3 g doses of cefotaxime to prevent postoperative infection,while the low dose group was treated with 1. 5 g dose cefotaxime. Results Both of the incidence rates of postoperative infection in the two groups were 6. 52%( P > 0. 05). The incidence rate of adverse reactions in the low dose group was 2. 17%,which was significantly lower than 13. 04% in the high dose group( P < 0. 05). The levels of albumin,hemoglobin and WBC in the two groups were significantly better than those before treatment( P < 0. 05),but there was no significant difference between the two groups( P > 0. 05). Conclusion The use of small dose cefotaxime in perioperative period of radical resection of lung cancer can effectively prevent postoperative infection and improve the body nutrition,it is safe and worthy of clinical promotion.
Objective To investigate the efficacy and safety of different doses of cefotaxime in the prevention of postoperative infection in perioperative period of radical resection of lung cancer. Methods Totally 92 patients with radical resection of lung cancer from February 2015 to August 2016 were randomly divided into the high dose group and the low dose group,46 cases in each group. The high dose group was treated with 3 g doses of cefotaxime to prevent postoperative infection,while the low dose group was treated with 1. 5 g dose cefotaxime. Results Both of the incidence rates of postoperative infection in the two groups were 6. 52%( P > 0. 05). The incidence rate of adverse reactions in the low dose group was 2. 17%,which was significantly lower than 13. 04% in the high dose group( P < 0. 05). The levels of albumin,hemoglobin and WBC in the two groups were significantly better than those before treatment( P < 0. 05),but there was no significant difference between the two groups( P > 0. 05). Conclusion The use of small dose cefotaxime in perioperative period of radical resection of lung cancer can effectively prevent postoperative infection and improve the body nutrition,it is safe and worthy of clinical promotion.
引文
[1]金利家,童树洪.3种头孢菌素类药物治疗下呼吸道感染的药物经济学分析[J].中国药业,2012,21(4):49-50.
[2]李崇阳,段忠玉,杨榆青,等.晚期肺癌化疗后肺部感染的病原学分析[J].昆明医科大学学报,2014,35(5):64-67.
[3]陈俊,庞林荣,李晖,等.肺癌放化疗患者呼吸系统二重感染病原菌分布与耐药性分析[J].中华医院感染学杂志,2016,26(9):1964-1966.
[4]Schlijper RC,Grutters JP,Houben R,et al.What to choose as radical local treatment for lung metastases from colo-rectal cancer:surgery or radiofrequency ablation?[J].Cancer Treatment Reviews,2014,40(1):60-67.
[5]来晓玲.术后应用头孢噻肟致药品不良反应的综合护理干预研究[J].中国药业,2013,22(5):89-90.
[6]朱水龙.重症监护室多重耐药菌的耐药性检测分析[J].中国药业,2012,21(22):48-49.
[7]张健,邓芳,张世勇,等.我院2007年至2011年铜绿假单胞菌临床分布及耐药分析[J].中国药业,2014,23(5):24-25.
[8]Mc Closkey P,Balduyck B,Van Schil PE,et al.Radical treatment of non-small cell lung cancer during the last 5 years[J].Eur J Cancer,2013,49(7):1555-1564.
[9]蒋春芳.头孢噻肟与亚胺培南西司他丁钠治疗新生儿败血症的效果比较研究[J].中外医疗,2016,35(12):125-127.
[10]林俊芳.青霉素钠联合头孢噻肟治疗新生儿化脓性脑膜炎疗效观察[J].首都食品与医药,2016,23(12):55-56.
[11]万宏梅,汤力.炎琥宁注射液与头孢噻肟联合布地奈德雾化吸入治疗小儿肺炎的临床疗效分析[J].中国初级卫生保健,2016,30(10):81-82.
[12]Griffioen GH,Toguri D,Dahele M,et al.Radical treatment of synchronous oligometastatic non-small cell lung carcinoma(NSCLC):Patient outcomes and prognostic factors[J].Lung Cancer,2013,82(1):95-102.
[13]万永艳.医院第3代头孢菌素类抗菌药物用量与肠杆菌科细菌耐药率相关性研究[J].中国药业,2016,25(23):43-45.
[14]张红梅,金彩辉,傅萍,等.专项整治前后医院抗菌药物使用情况及对细菌耐药性的影响[J].中国药业,2016,25(24):77-80.
[15]黄晓龙,周晓芳,王增,等.肺癌根治术围术期使用不同剂量头孢噻肟预防术后感染的效果观察[J].中国药房,2015,26(33):4655-4657.
[2]李崇阳,段忠玉,杨榆青,等.晚期肺癌化疗后肺部感染的病原学分析[J].昆明医科大学学报,2014,35(5):64-67.
[3]陈俊,庞林荣,李晖,等.肺癌放化疗患者呼吸系统二重感染病原菌分布与耐药性分析[J].中华医院感染学杂志,2016,26(9):1964-1966.
[4]Schlijper RC,Grutters JP,Houben R,et al.What to choose as radical local treatment for lung metastases from colo-rectal cancer:surgery or radiofrequency ablation?[J].Cancer Treatment Reviews,2014,40(1):60-67.
[5]来晓玲.术后应用头孢噻肟致药品不良反应的综合护理干预研究[J].中国药业,2013,22(5):89-90.
[6]朱水龙.重症监护室多重耐药菌的耐药性检测分析[J].中国药业,2012,21(22):48-49.
[7]张健,邓芳,张世勇,等.我院2007年至2011年铜绿假单胞菌临床分布及耐药分析[J].中国药业,2014,23(5):24-25.
[8]Mc Closkey P,Balduyck B,Van Schil PE,et al.Radical treatment of non-small cell lung cancer during the last 5 years[J].Eur J Cancer,2013,49(7):1555-1564.
[9]蒋春芳.头孢噻肟与亚胺培南西司他丁钠治疗新生儿败血症的效果比较研究[J].中外医疗,2016,35(12):125-127.
[10]林俊芳.青霉素钠联合头孢噻肟治疗新生儿化脓性脑膜炎疗效观察[J].首都食品与医药,2016,23(12):55-56.
[11]万宏梅,汤力.炎琥宁注射液与头孢噻肟联合布地奈德雾化吸入治疗小儿肺炎的临床疗效分析[J].中国初级卫生保健,2016,30(10):81-82.
[12]Griffioen GH,Toguri D,Dahele M,et al.Radical treatment of synchronous oligometastatic non-small cell lung carcinoma(NSCLC):Patient outcomes and prognostic factors[J].Lung Cancer,2013,82(1):95-102.
[13]万永艳.医院第3代头孢菌素类抗菌药物用量与肠杆菌科细菌耐药率相关性研究[J].中国药业,2016,25(23):43-45.
[14]张红梅,金彩辉,傅萍,等.专项整治前后医院抗菌药物使用情况及对细菌耐药性的影响[J].中国药业,2016,25(24):77-80.
[15]黄晓龙,周晓芳,王增,等.肺癌根治术围术期使用不同剂量头孢噻肟预防术后感染的效果观察[J].中国药房,2015,26(33):4655-4657.